July 29, 2025
Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital
Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company
Merck Announces $3 Billion Cost-Cutting and Restructuring Plan
Merck; cost cutting; restructuring; job cuts; real estate reduction; Keytruda; pharmaceutical industry; Q2 2025 financials
FDA Reverses Course, Allows Sarepta to Resume Duchenne Gene Therapy Shipments
FDA; Sarepta Therapeutics; Duchenne muscular dystrophy; Elevidys; gene therapy; safety pause; shipment resumption
Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal
Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement
Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale
Adaptimmune; layoffs; cell therapy sale; US WorldMeds; restructuring; biotech workforce reduction; TECELRA; lete-cel; afami-cel; uza-cel
Apellis’ Empaveli Gains FDA Approval for Broad C3 Glomerulopathy Use, Setting Up Competition with Novartis’ Fabhalta
Apellis; Empaveli; FDA approval; C3 glomerulopathy; primary immune complex membranoproliferative glomerulonephritis; Novartis; Fabhalta; pegcetacoplan; iptacopan; proteinuria; kidney disease